Company: INDP
Filing Date: 2025-02-12
Form Type: S-1
Source: 0001493152-25-006068
Chunk: 138

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-02-12
Form: S-1
Chunk 138
---
 shares than are offered under this prospectus in order to receive aggregate gross proceeds equal to the $20.0       
 million Commitment Amount under the Purchase Agreement. If we choose to do so and otherwise satisfy the conditions in the Purchase          
 Agreement, we must first register for resale under the Securities Act such additional shares of common stock. The number of shares          
 ultimately offered for resale by YA is dependent upon the number of shares of common stock we sell to YA under the Purchase Agreement.      |
| (3) | Assumes                                                                                                                                     
 the sale of all shares being offered pursuant to this prospectus.                                                                           |
| (4) | YA                                                                                                                                          
 is a fund managed by Yorkville Advisors Global, LP or Yorkville LP. Yorkville Advisors Global II, LLC or Yorkville LLC is the General       
 Partner of Yorkville LP. All investment decisions for YA are made by Yorkville LLC’s President and Managing Member, Mr. Mark                
 Angelo. The business address of YA is 1012 Springfield Avenue, Mountainside, NJ 07092.                                                      |

| 98 |

<div align='center'>DESCRIPTION OF SECURITIES</div>

This section describes the general terms and provisions of the shares of our common stock, par value $0.01 per share, and preferred stock, par value $0.01 per share, and some of the provisions of our certificate of incorporation and bylaws and of the Delaware General Corporation Law, or DGCL. This description is only a summary. Our amended and restated certificate of incorporation, as amended, and our amended and restated bylaws on the registration statement to which this prospectus relates. You should read our amended and restated certificate of incorporation and our amended and restated bylaws for additional information before you buy any of our common stock, preferred stock or other securities. See “Where You Can Find More Information.”

General

Our authorized capital stock consists of shares made up of 200,000,000 shares of common stock, par value $0.01 per share and 5,000,000 shares of undesignated preferred stock, par value $0.01 per share.

As of February 11, 2025, there were 14,123,284 shares of common stock outstanding, and there were 24 holders of record of our common stock.

Common stock

Each share of our common stock outstanding is entitled to one vote on all matters on which our stockholders generally are entitled to vote. However, holders of our common stock are not be entitled to vote on any amendment